Who the Forteo label covers
Teriparatide is a version of part of human parathyroid hormone. The branded Forteo pen contains 560 mcg in 2.24 mL, with 28 labeled doses of 20 mcg.
The U.S. label covers osteoporosis treatment in postmenopausal women, increasing bone mass in men with primary or hypogonadal osteoporosis, and treatment in men and women with osteoporosis associated with sustained systemic glucocorticoids. In each case, the label applies to people at high fracture risk or people for whom other available osteoporosis treatment failed or was intolerable.
Sources for this section
What the fracture trial found
In a randomized trial of postmenopausal women with prior spine fractures, about 5 in 100 in the 20 mcg teriparatide group had a new spine fracture on X-ray, compared with about 14 in 100 in the placebo group. Participants were followed for a median of 21 months. The result directly addresses spine fractures in that study population.
Designing Longevity’s existing clinical evidence rating, when current, applies to the Forteo 20 mcg presentation and new spine fractures in postmenopausal women with osteoporosis at very high fracture risk, particularly those with prior spine fractures. The indication for men concerns an increase in bone mass.
Sources for this section
What to discuss before starting
Discuss fracture history, prior osteoporosis treatment and the planned length of treatment. The label says extended use beyond two lifetime years is considered only if fracture risk remains high or becomes high again.
The label calls out serious allergic reactions, high blood calcium and conditions that put people at greater risk of osteosarcoma, a type of bone cancer. Examples include past radiation involving the skeleton and certain bone cancers. A clinician can review these risks and the plan for follow-up.